Search results
Results from the WOW.Com Content Network
The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. [2] Hypertension (high blood pressure) is the most important contributing risk factor for stroke and cerebrovascular diseases as it can change the structure of blood vessels and result in atherosclerosis . [ 5 ]
5327 18791 Ensembl ENSG00000104368 ENSMUSG00000031538 UniProt P00750 P11214 RefSeq (mRNA) NM_033011 NM_000930 NM_000931 NM_001319189 NM_008872 RefSeq (protein) NP_000921 NP_001306118 NP_127509 NP_032898 Location (UCSC) Chr 8: 42.17 – 42.21 Mb Chr 8: 23.25 – 23.27 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue-type plasminogen activator, short name tPA, is a protein that ...
Stroke is a peer-reviewed medical journal published monthly by Lippincott Williams & Wilkins on behalf of the American Heart Association. It covers research on cerebral circulation and related diseases, including clinical research on assessment of risk for stroke , diagnosis, prevention, and treatment, as well as rehabilitation. [ 1 ]
And, for the first time, it includes the possibility of using a glucagon-like protein-1 (GLP-1) receptor agonist medication to lower the risk of heart disease and stroke.
Some causes of hemorrhagic stroke are hypertensive hemorrhage, ruptured aneurysm, ruptured AV fistula, transformation of prior ischemic infarction, and drug-induced bleeding. [74] They result in tissue injury by causing compression of tissue from an expanding hematoma or hematomas.
A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...
Cerebral infarction, also known as an ischemic stroke, is the pathologic process that results in an area of necrotic tissue in the brain (cerebral infarct). [1] In mid to high income countries, a stroke is the main reason for disability among people and the 2nd cause of death. [2]
Medications are used to reverse the symptoms of extrapyramidal side effects caused by antipsychotics or other drugs, by either directly or indirectly increasing dopaminergic neurotransmission. The treatment varies by the type of the EPS, but may involve anticholinergic agents such as procyclidine, benztropine, diphenhydramine, and trihexyphenidyl.